Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma

BACKGROUND: Cyclin-dependent kinases 2/4/6 (CDK2/4/6) play critical roles in cell cycle progression, and their deregulations are hallmarks of hepatocellular carcinoma (HCC). METHODS: We used the combination of computational and experimental approaches to discover a CDK2/4/6 triple-inhibitor from FDA...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ying, Ke, Kun-Bin, Xia, Zhong-Kun, Li, Hong-Jian, Su, Rong, Dong, Chao, Zhou, Feng-Mei, Wang, Lin, Chen, Rong, Wu, Shi-Guo, Zhao, Hui, Gu, Peng, Leung, Kwong-Sak, Wong, Man-Hon, Lu, Gang, Zhang, Jian-Ying, Jiang, Bing-Hua, Qiu, Jian-Ge, Shi, Xi-Nan, Lin, Marie Chia-mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879659/
https://www.ncbi.nlm.nih.gov/pubmed/33579185
http://dx.doi.org/10.1186/s10020-021-00269-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879659/
https://www.ncbi.nlm.nih.gov/pubmed/33579185
http://dx.doi.org/10.1186/s10020-021-00269-4

Ejemplares similares